PLAsticity, Security and Tolerance to Intermittent Hypoxic Conditioning Following Stroke (PLASTIHC)

By inducing endogenous neuroprotection, hypoxic post-conditioning following stroke may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies.

The investigators thus hypothesize that hypoxic post-conditioning represents a safe therapeutic strategy post-stroke. The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care.

The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention.

The investigators will further investigate the potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will also be investigated, based on biological and imagery markers.

Study Overview

• Status: Not yet recruiting
• Conditions: Stroke, Ischemic; Stroke Sequelae
• Intervention / Treatment: Drug: Hypoxia, intermittent; Other: Normoxia

Detailed Description

Stroke is the second leading cause of death and the third leading cause of disability-adjusted life-years worldwide. If acute stroke therapy has decreased mortality, more than 50% of stroke survivors are left with sensorimotor and cognitive deficiencies. Recovery and rehabilitation treatments, aiming at inducing neuroplasticity, maximizing function in unaffected brain areas or implementing compensatory strategies to improve overall function, benefit from an extensive time window that ranges from days to months. Their development is urgently needed.

Several endogenous neuroprotective mechanisms are spontaneously engaged following stroke to achieve neuroprotection and stimulate brain repairing processes. Conditioning the central nervous system can trigger endogenous mechanisms of neuroprotection. Conditioning refers to a procedure by which a potentially deleterious stimulus is applied near to but below the threshold of damage to the organism. While hypoxia is well recognized as a common underlying mechanism of many pathological conditions, experimental data indicate that exposure to specific doses of hypoxia (by breathing a hypoxic gas mixture) can be neuroprotective.

Preconditioning is defined as the exposure to the conditioning stimulus before injury onset, to induce tolerance or resistance to the subsequent injury. Postconditioning refers to the application of the conditioning stimulus after injury or damage, to stimulate tissue reparation or neuroplasticity. As stroke is an unpredictable event, translating hypoxic preconditioning to clinical practice seems difficult. However, developing postconditioning strategies seems of clinical and rehabilitative relevance. Thus, an increase in neuronal salvage and neurogenesis, along with an increase in brain-derived neurotrophic factor expression and a reduced neuroinflammation were shown in murine models of hypoxic conditioning following ischemic stroke.

By inducing endogenous neuroprotection, hypoxic conditioning may represent a harmless and efficient non-pharmacological innovative neuro-therapeutic modality aiming at inducing neuroplasticity and brain repair, as supported by many preclinical studies.

The main working hypothesis is that hypoxic postconditioning may represent a safe therapeutic strategy post-stroke.

The investigators further hypothesize that hypoxic conditioning could enhance neuroplasticity and function in combination with conventional rehabilitative care.

The primary study endpoint will be safety. Safety will be assessed through the clinical review of the adverse events over the duration of the study, every 48 hours by a trained evaluator, blinded for the therapeutic intervention.

All adverse events will be evaluated and quoted in accordance with National Institute of Health Common Criteria for Terminology for Adverse Events 5.0 (NIH CCTAE) recommendations, particularly with respect to Sub-sections "Cardiac disorders ", "Nervous system disorders" and "Vascular Disorders". Safety assessments will be performed every 48 hours, throughout the 8-week conditioning period, in addition to the conventional clinical follow-up performed in the rehabilitation unit.

The potential functional benefits of such a therapeutic approach on motor function, gait, balance, and cognition will also be further investigated. The neurophysiological substrates of hypoxic conditioning-triggered neuroplasticity at a subacute delay post-stroke will be investigated, based on biological (serum inflammatory markers, growth and neurogenesis biomarkers) and imagery markers (morphological MRI sequences, functional connectivity (resting state), and brain vascularization).

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Sébastien BAILLIEUL, MD, PhD; Phone Number: +33 0623574355; Email: sbaillieul@chu-grenoble.fr
• Study Contact Backup: Name: Olivier DETANTE, Prof.; Email: odetante@chu-grenoble.fr

Study Locations

• France
  • Veuillez Sélectionner Une Région.
    • Grenoble, Veuillez Sélectionner Une Région., France, 38000
      • Grenoble Aalpes University Hospital
      • Sub-Investigator: Isabelle FAVRE-WIKI, MD
      • Sub-Investigator: Katia GARAMBOIS, MD
      • Contact: Sébastien BAILLIEUL, MD, PhD; Phone Number: +33 0623574355; Email: sbaillieul@chu-grenoble.fr
      • Contact: Detante Olivier, Prof.; Email: odetante@chu-grenoble.fr
      • Principal Investigator: Sébastien BAILLIEUL, MD, PhD
      • Principal Investigator: Olivier DETANTE, MD, PhD
      • Sub-Investigator: Stéphane DOUTRELEAU, MD, PhD
      • Sub-Investigator: Jean-Louis PEPIN, MD, PhD
      • Sub-Investigator: Sarah ALEXANDRE, MD
      • Sub-Investigator: Alexandre KRAINIK, MD, PhD
      • Sub-Investigator: Arnaud ATTYE, MD, PhD
      • Sub-Investigator: Michel GUINOT, MD, PhD
      • Sub-Investigator: Renaud Tamisier, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients with minor cerebral infarction with NIHSS < or equal to 5 will be included in the protocol;
• Cerebral infarction occurring one month (±1 week) before the planned start of hypoxic exposure;
• Age ≥18 years;
• A first, unilateral, ischemic, supra-tentorial hemispheric stroke, confirmed by magnetic resonance imaging;
• Modified Rankin Scale score between 1 and 3, defining mild to moderate residual functional disability.
• A person affiliated with the social security system or benefits from such a system;
• A person who has given written informed consent.

Exclusion Criteria:

• Patients who are minors or over 85 years of age, pregnant or breastfeeding women, or women of childbearing potential in the absence of highly effective contraception;
• Stroke of the brainstem or cerebellum ;
• Severe aphasia, limiting the ability to understand the protocol;
• History of central or peripheral neurological pathology;
• Modified Rankin Scale score >0 before stroke;
• Known severe untreated obstructive sleep apnea syndrome, defined as an apnea-hypopnea index ≥ 30 events per hour of sleep;
• Pre-existing hypoxemic lung disease (such as chronic obstructive pulmonary disease);
• Heart failure, defined as an ejection fraction ≤40% ;
• History of high altitude pathology;
• Scheduled stay at altitude (> 2500 m) during the study period ;
• Migraine;
• History of rheumatological or orthopedic disease of the lower limbs, amputation of the lower limb.
• Contraindication to magnetic resonance imaging;
• Subjects who cannot be contacted in an emergency;
• Subject in exclusion period of another study;
• Subject under administrative or judicial supervision;
• Persons referred to in Articles L1121-5 to L1121-8 of the "Code de la Santé Publique" (corresponds to all protected persons: pregnant women, women in labor, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PHASE 1- Dose escalation protocol; 4-step dose-escalation protocol with increasing doses of intermittent hypoxia and continuous reassessment of safety criteria (primary endpoint). Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment. For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored: 90% for stage 1 (n=1 patient), 85% for stage 2 (n=3 patients), 80% for stage 3 (n=3 patients), 75% for stage 4 (n=3 patients).	Drug: Hypoxia, intermittent; The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia. Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment. For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.; Other Names: Hypoxia; Hypoxic conditioning
Active Comparator: PHASE 2 - Intermittent hypoxia group; Group exposed to an intermittent hypoxic stimulus (n=20, target pulsed saturation in dioxygen 75%). The device used is a gas mixer already in use in the unit and used in current clinical practice and research in our team (Altitrainer®, Sport and Medical TEChnologies S.A. (SMTEC S.A.), Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia. Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment. For hypoxic exposure, the FiO2 will be set individually to achieve the targeted level of desaturation.	Drug: Hypoxia, intermittent; The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia. Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment. For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.; Other Names: Hypoxia; Hypoxic conditioning
Sham Comparator: PHASE 2 - Sham (Normoxia) group; Normoxia group (n=10, FiO2 = 21%). The same setting will be used as in the Intermittent hypoxia group, but subjects will breathe ambient air throughout the conditioning procedure.	Other: Normoxia; The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Secondary adverse events	The safety of such a therapeutic strategy will be assessed by systematic screening for adverse events at each conditioning session and at follow-up visits throughout the duration of exposure (8 weeks) by a trained experimenter, blinded to the therapeutic intervention. All adverse events will be assessed and scored as a composite endpoint according to the NIH CCTAE 5.0 (National Institute of Health Common Terminology Criteria for Adverse Events), including in particular those listed in the sub-sections on "Cardiological Pathologies", "Central Nervous System Pathologies" and "Vascular Pathologies".	Through study completion, an average of 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fugl-Meyer	Function - Fugl-Meyer motor function Score range: 0-100 Higher values indicate better performance. A score of 96-99 indicates light motor incoordination A score of 85-95 indicates hemiparesis A score ≤ 84 indicates hemiplegia	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
New Functional ambulation category (nFAC) score	Function - New Functional ambulation category (nFAC) score Score range: 0-5 A score of 0 indicates no functional ability to walk A score of 5 indicates independent walking	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Prospective collection of number of falls	Function - Prospective collection of number of falls	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Modified Rankin Scale (mRS)	Activity limitation - Modified Rankin Scale (mRS) Score range: 0-6 The mRS scores range from à (no symptom) to 6 (death)	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Barthel index	Activity limitation - Barthel index Score range: 0-100 The higher the score, the better the function and the independence	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
16-item Stroke Impact Scale	Participation The higher the score, the better the performance.	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
10-metre walk test	Mobility - Instrumented 10-metre walk test, carried out at spontaneous walking speed, 3 trials: collection of quantitative spatiotemporal step parameters and their variability, collection of walking speed.	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Timed-up and Go test	Mobility - Timed-up and Go test: 3 trials	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Montreal Cognitive Assessment	Neuropsychological assessment Score range: 0-30 Normal if >26/30 The higher the score, the better the cognitive performance.	Phase 1: Inclusion, 2 months; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Morphological sequences	The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. High-resolution anatomical sequences: T1, T2, FLAIR, for calculation of lesion volume and delineation of lesion mask.	Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Diffusion and perfusion sequences	The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Bolus perfusion (gadolinium) T1 and Diffusion Tensor Imaging (DTI, 60 directions or High Angular Resolution Diffusion Imaging (HARDI)), allowing calculation of the Apparent Diffusion Coefficient (ADC) map.	Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Cerebral blood flow	The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Cerebral vasoreactivity (to a hypercapnic stimulus) assessed by Arterial Spin Labelling (ASL) and Blood oxygenation level-dependent (BOLD) sequences.	Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Magnetic resonance imagery - Resting state functional magnetic resonance imaging (fMRI)	The acquisitions will be performed on a 3 Tesla magnetic resonance imaging (MRI) machine. Functional connectivity measurements.	Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months
Cerebral Blood Flow	Cerebral blood flow will be assessed by measuring the flow velocity in the middle cerebral artery (MCAv), estimated by continuous measurement of the right middle cerebral artery using a 2 megahertz (MHz) pulsed transcranial Doppler (TCD) (MultiDop T, Compumedics Germany GmbH, Germany). Following standardized research techniques, the Doppler probe will be fixed to the temporal window with the aid of a helmet (DiaMon, Compumedics Germany GmbH) to maintain an optimal insonation position throughout the study and thus avoid any movement artifact.	Phase 1: Inclusion; Phase 2: Inclusion, 2 months, 6 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biomarkers of hypoxic conditioning - Brain Derived Neurotrophic Factor (BDNF)	Phase 2 only. A blood sample collection will be performed to secondary assess the Brain-Derived Neurotrophic Factor (BDNF) levels in the serum. Unit: pg/ml	Phase 2: Inclusion, 2 months, 6 months
Biomarkers of hypoxic conditioning - Erythropoietin (EPO)	Phase 2 only. A blood sample collection will be performed to secondary assess the Erythropoietin (EPO) levels in the serum. Unit: milli-international unit/mL	Phase 2: Inclusion, 2 months, 6 months
Biomarkers of hypoxic conditioning - Hypoxia inducible factor 1	Phase 2 only. A blood sample collection will be performed to secondary assess the Hypoxia inducible factor 1 levels in the blood. Analytic method: RNA extraction Unit: Normalised copy number	Phase 2: Inclusion, 2 months, 6 months
Biomarkers of hypoxic conditioning - Vascular Endothelial Growth Factor (VEGF)	Phase 2 only. A blood sample collection will be performed to secondary assess the VEGF levels in the blood. Analytic method: ELISA	Phase 2: Inclusion, 2 months, 6 months

Collaborators and Investigators

• Sponsor: University Hospital, Grenoble
• Collaborators: Agir pour les maladies chroniques

Publications and helpful links

General Publications

• Verges S, Chacaroun S, Godin-Ribuot D, Baillieul S. Hypoxic Conditioning as a New Therapeutic Modality. Front Pediatr. 2015 Jun 22;3:58. doi: 10.3389/fped.2015.00058. eCollection 2015.
• Baillieul S, Chacaroun S, Doutreleau S, Detante O, Pepin JL, Verges S. Hypoxic conditioning and the central nervous system: A new therapeutic opportunity for brain and spinal cord injuries? Exp Biol Med (Maywood). 2017 Jun;242(11):1198-1206. doi: 10.1177/1535370217712691.
• Burtscher J, Syed MMK, Lashuel HA, Millet GP. Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease? Mov Disord. 2021 Apr;36(4):857-861. doi: 10.1002/mds.28544. Epub 2021 Feb 27.

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2023
• Primary Completion (Anticipated): December 31, 2023
• Study Completion (Anticipated): December 31, 2025

Study Registration Dates

• First Submitted: October 5, 2021
• First Submitted That Met QC Criteria: January 13, 2022
• First Posted (Actual): January 27, 2022

Study Record Updates

• Last Update Posted (Actual): May 23, 2023
• Last Update Submitted That Met QC Criteria: May 22, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Safety; Stroke; Recovery; Biomarkers; Intermittent hypoxia; Hypoxic conditioning
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Stroke; Ischemic Stroke
• Other Study ID Numbers: 2021-A00104-37

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data collected for the study, including deidentified individual participant data will be made available to others following the publication of this article, for academic purposes (e.g., meta-analyses) on request to the principal investigator, after the publication of the results of the present study.
• IPD Sharing Time Frame: After the publication of the results of the present study.
• IPD Sharing Access Criteria: Data collected for the study, including deidentified individual participant data will be made available to others following the publication of this article, for academic purposes (e.g., meta-analyses) on request to the principal investigator.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No